Estados financieros detallados de Lifecore Biomedical, Inc. (LFCR): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Lifecore Biomedical, Inc. registró ingresos de $129.5M en el último ejercicio fiscal, con un CAGR de 5 años del 5.1%.
Márgenes de los últimos 12 meses: margen bruto 29.7%, margen operativo -2.1%, margen neto -30.4%.
Al precio actual de $4.16, LFCR presenta beneficios negativos (P/E no significativo) y un ROE del -376.95%. La capitalización bursátil es de $156M.
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $532.3M | $524.2M | $557.6M | $160.1M | $100.9M | $111.3M | $103.3M | $128.3M | $128.9M | $129.5M |
| Coste de Ventas | $449.1M | $445.9M | $476.6M | $120.7M | $61.9M | $72.2M | $75.3M | $86.4M | $88.6M | $88.9M |
| Beneficio Bruto | $83.2M | $78.3M | $81.0M | $39.4M | $38.9M | $39.1M | $28.0M | $41.9M | $40.3M | $40.6M |
| I+D | $9.5M | $12.8M | $11.5M | $7.6M | $6.7M | $7.8M | $8.7M | $8.6M | $8.3M | $8.5M |
| Generales y Administrativos | $58.2M | $52.0M | $64.1M | $40.7M | $27.7M | $34.7M | $39.0M | $40.5M | $44.0M | $33.4M |
| Gastos Operativos | $67.7M | $64.8M | $75.5M | $65.3M | $47.8M | $50.9M | $49.8M | $50.7M | $57.5M | $41.9M |
| Beneficio Operativo | $15.5M | $11.8M | -$8.0M | -$25.9M | -$8.8M | -$11.8M | -$21.8M | -$8.8M | -$17.2M | -$1.3M |
| EBITDA | $26.7M | $25.0M | $23.5M | -$7.2M | -$987000 | $12.8M | -$33.2M | $35.6M | -$8.8M | $8.2M |
| Gastos por Intereses | $1.8M | $1.9M | $5.2M | $4.6M | $8.9M | $15.6M | $17.6M | $18.1M | $21.8M | -$2.2M |
| Beneficio Antes de Impuestos | $15.0M | $16.4M | $3.6M | -$30.6M | -$29.8M | -$20.7M | -$63.9M | $9.5M | -$38.7M | -$30.2M |
| Impuestos | $4.3M | -$9.4M | $1.5M | -$8.8M | -$6.3M | -$5.2M | $308000 | $183000 | $43000 | $577714 |
| Beneficio Neto | $10.6M | $24.8M | $2.1M | -$38.2M | -$32.3M | -$116.7M | -$99.6M | $12.0M | -$38.7M | -$30.8M |
| BPA | $0.39 | $0.90 | $0.07 | $-1.31 | $-1.12 | $-3.97 | $-3.32 | $0.39 | $-1.27 | $-0.92 |
| BPA Diluido | $0.38 | $0.89 | $0.07 | $-1.31 | $-1.12 | $-3.97 | $-3.32 | $0.33 | $-1.27 | $-0.93 |
| Acciones en Circulación (Diluidas) | $27.7M | $27.9M | $28.6M | $29.2M | $29.3M | $29.5M | $30.0M | $36.7M | $34.8M | $37.4M |
Balance (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $5.4M | $2.9M | $1.1M | $360000 | $1.2M | $991000 | $19.1M | $8.5M | $8.3M | $17.5M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | $45.9M | $53.9M | $69.6M | $76.2M | $41.4M | $38.3M | $29.0M | $31.2M | $43.7M | $33.8M |
| Inventario | $25.3M | $31.8M | $54.1M | $66.3M | $63.1M | $36.0M | $40.8M | $40.0M | $32.3M | $29.1M |
| Activos Corrientes | $81.3M | $97.1M | $133.0M | $157.1M | $148.3M | $116.7M | $93.9M | $81.0M | $85.7M | $82.3M |
| Inmovilizado Material | $133.2M | $159.6M | $200.0M | $217.7M | $137.4M | $124.2M | $138.7M | $149.2M | $129.0M | $127.3M |
| Fondo de Comercio | $54.8M | $54.5M | $76.7M | $69.4M | $33.9M | $13.9M | $13.9M | $13.9M | $13.9M | $13.9M |
| Activos Intangibles | $22.8M | $21.8M | $45.2M | $38.1M | $25.6M | $4.2M | $4.2M | $4.2M | $4.2M | 0 |
| Activos Totales | $358.0M | $404.7M | $519.1M | $541.3M | $502.9M | $274.7M | $253.5M | $254.0M | $239.3M | $232.2M |
| Cuentas por Pagar | $24.5M | $34.7M | $54.0M | $51.6M | $16.3M | $13.0M | $22.1M | $16.3M | $8.2M | $5.8M |
| Deuda a Corto | $7.9M | $31.9M | $61.8M | $89.0M | $29.0M | $138.2M | $580000 | $943000 | $3.4M | $773000 |
| Pasivos Corrientes | $51.5M | $88.4M | $137.1M | $164.4M | $101.9M | $176.6M | $39.3M | $38.9M | $30.2M | $23.6M |
| Deuda a Largo | $42.3M | $37.4M | $87.7M | $101.4M | $164.9M | $97.6M | $101.1M | $123.7M | $127.0M | $135.6M |
| Pasivos Totales | $129.9M | $152.1M | $248.9M | $310.3M | $300.1M | $186.9M | $257.8M | $242.6M | $238.0M | $246.4M |
| Reservas | $84.5M | $109.3M | $109.7M | $71.2M | $38.6M | -$79.0M | -$178.5M | -$166.5M | -$205.2M | -$223.2M |
| Patrimonio Neto | $226.6M | $252.6M | $270.1M | $231.0M | $202.8M | $87.8M | -$4.2M | $11.3M | $1.3M | -$14.2M |
| Deuda Total | $54.0M | $72.9M | $152.5M | $221.1M | $215.9M | $247.8M | $112.6M | $133.6M | $130.8M | $142.6M |
| Deuda Neta | $48.6M | $70.0M | $151.4M | $220.8M | $214.7M | $246.8M | $93.5M | $125.1M | $122.6M | $125.1M |
| Capital Circulante | $29.8M | $8.7M | -$4.0M | -$7.3M | $46.4M | -$59.9M | $54.6M | $42.2M | $55.5M | $58.7M |
Flujo de Caja (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | $10.7M | $24.9M | $411000 | -$15.1M | -$32.3M | -$116.7M | -$99.6M | $12.0M | -$38.7M | -$31.1M |
| Amortizaciones | $10.7M | $12.4M | $15.2M | $18.8M | $19.9M | $18.1M | $13.2M | $8.0M | $8.0M | $6.8M |
| Compensación en Acciones | $4.0M | $4.4M | $3.6M | $2375 | $3.4M | $2.6M | $3.6M | $6.2M | $10.2M | $6.2M |
| Cambio en Capital Circulante | $584000 | -$10.1M | -$1.2M | -$27.7M | $9.8M | -$3.1M | $19.8M | -$3.7M | -$4.7M | -$2.3M |
| Flujo de Caja Operativo | $29.3M | $19.8M | $16.0M | -$17.0M | $16.5M | -$22.6M | -$17.4M | $257000 | -$206000 | $12.6M |
| Inversiones (CapEx) | -$22.6M | -$33.6M | -$44.7M | -$26.7M | -$25.2M | -$29.9M | -$21.5M | -$18.4M | -$13.4M | -$6.3M |
| Adquisiciones | -$2.5M | -$4.1M | -$59.9M | $2.4M | 0 | $73.5M | $16.7M | 0 | $7.0M | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -$1.9M |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | $6.7M | -$13.8M | -$28.7M | -$43.7M | -$8.8M | -$52.5M | -$38.9M | -$18.1M | -$13.6M | $6.2M |
Crecimiento y Márgenes (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | -1.5% | +6.4% | -71.3% | -37.0% | +10.3% | -7.2% | +24.2% | +0.5% | +0.5% | |
| Crecimiento Beneficio Neto (anual) | +134.5% | -91.5% | -1899.8% | +15.4% | -261.4% | +14.7% | +112.1% | -422.3% | +20.5% | |
| Crecimiento BPA (anual) | +130.8% | -91.7% | -1851.3% | +14.5% | -254.5% | +16.4% | +111.7% | -425.6% | +27.6% | |
| Cambio en Acciones (anual) | +1.0% | +2.5% | +1.9% | +0.5% | +0.6% | +1.7% | +22.4% | -5.0% | +7.3% | |
| Crecimiento FCF (anual) | -305.1% | -107.9% | -52.3% | +80.0% | -500.2% | +25.9% | +53.4% | +24.9% | +145.7% | |
| Margen Bruto | 15.6% | 14.9% | 14.5% | 24.6% | 38.6% | 35.1% | 27.1% | 32.6% | 31.3% | 31.4% |
| Margen Operativo | 2.9% | 2.3% | -1.4% | -16.2% | -8.7% | -10.6% | -21.1% | -6.9% | -13.4% | -1.0% |
| Margen EBITDA | 5.0% | 4.8% | 4.2% | -4.5% | -1.0% | 11.5% | -32.1% | 27.8% | -6.8% | 6.4% |
| Margen Neto | 2.0% | 4.7% | 0.4% | -23.9% | -32.0% | -104.9% | -96.4% | 9.4% | -30.0% | -23.8% |
| Margen FCF | 1.3% | -2.6% | -5.1% | -27.3% | -8.7% | -47.2% | -37.7% | -14.1% | -10.6% | 4.8% |
| Tasa Impositiva Efectiva | 28.9% | -57.1% | 41.7% | 28.6% | 21.3% | 25.2% | -0.5% | 1.9% | -0.1% | -1.9% |
Datos por Acción (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $0.24 | $-0.49 | $-1.00 | $-1.50 | $-0.30 | $-1.78 | $-1.30 | $-0.49 | $-0.39 | $0.17 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $27.5M | $27.7M | $28.4M | $29.2M | $29.3M | $29.5M | $30.0M | $30.5M | $34.8M | $33.3M |
Qué mirar en Salud / Farma
El pipeline de I+D es el activo invisible. Patentes que caducan = ingresos que evaporan. Mira innovación y flujo de caja.
- I+D / Ingresos — Indica inversión en pipeline futuro. Farma seria reinvierte 15-20%
- Crecimiento EPS 5y — Tras caducidad de patentes, ¿siguen creciendo?
- Margen bruto — Farma de marca >70%. Genéricos mucho más bajo — define el tipo de negocio
- FCF / Net Income — Calidad del beneficio — farma grande debería convertir >90%
- ROIC — Capital reinvertido con eficiencia — clave en farma por ciclos de I+D largos
- Deuda neta / EBITDA — Adquisiciones de farma generan mucha deuda — ojo al post-M&A
- P/E vs historial 10y propio — La mejor comparación es con su propia historia, no con competidores
Rentabilidad
| Rentabilidad sobre capital | -376.95% |
| Rentabilidad sobre capital invertido | -1.25% |
| Rentabilidad sobre activos | -16.25% |
| Margen bruto | 29.68% |
| Margen operativo | -2.12% |
| Margen neto | -30.40% |
Salud financiera
| Deuda / Patrimonio | 9.64 |
| Ratio corriente | 3.87 |
Ratios Clave (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | 35.90 | 15.67 | 132.62 | -8.27 | -10.39 | -2.49 | -2.39 | 14.41 | -5.29 | -8.89 |
| P/VC | 1.70 | 1.55 | 1.04 | 1.37 | 1.68 | 3.31 | -56.23 | 15.14 | 175.14 | -19.16 |
| P/V | 0.72 | 0.75 | 0.50 | 1.97 | 3.38 | 2.61 | 2.30 | 1.34 | 1.82 | 2.10 |
| Margen Bruto | 15.6% | 14.9% | 14.5% | 24.6% | 38.6% | 35.1% | 27.1% | 32.6% | 31.3% | 31.4% |
| Margen Operativo | 2.9% | 2.3% | -1.4% | -16.2% | -8.7% | -10.6% | -21.1% | -6.9% | -13.4% | -1.0% |
| Margen Neto | 2.0% | 4.7% | 0.4% | -23.9% | -32.0% | -104.9% | -96.4% | 9.4% | -30.0% | -23.8% |
Empresas relacionadas: ACB · ACHV · BIOA · CGC · CVRX · IMMP · OMI
Explorar sector: Healthcare · Drug Manufacturers - Specialty & Generic
Más secciones de LFCR: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones